The first-generation ALK inhibitor crizotinib and the second-generation inhibitors alectinib, ceritinib, bigatinib, and ensartinib are effective in treating NSCLC with activating ALK translocations; however, their efficacy in BMs shows significant differences [45,46,47]. This evidence concerns the gene ALK and non-small cell lung carcinoma.